New drug duo targets tough bladder cancers

NCT ID NCT04963153

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

Summary

This early-stage trial is testing a combination of two targeted drugs, erdafitinib and enfortumab vedotin, for people with advanced bladder cancer that has spread and has specific genetic changes (FGFR2/3). The main goals are to find the safest and most effective dose of the drug combination and to check for side effects. The study is for adults whose cancer has worsened after trying standard chemotherapy and immunotherapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
Los Angeles General Medical Center

Los Angeles, California, 90033, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
NYP/Weill Cornell Medical Center

New York, New York, 10065, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
UCHealth University of Colorado Hospital

Aurora, Colorado, 80045, United States
USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390, United States
University Health Network-Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States

Conditions

Explore the condition pages connected to this study.